- Trials with a EudraCT protocol (541)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
541 result(s) found for: abbvie.
Displaying page 1 of 28.
EudraCT Number: 2016-002491-26 | Sponsor Protocol Number: M15-942 | Start Date*: 2017-03-17 |
Sponsor Name:AbbVie Deutschland GmbH & Co. KG | ||
Full Title: An Open-Label, Multicenter Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Combination with Sofosbuvir and Ribavirin in Chronic Hepatitis C (HCV) Infected Subjects Who Have Experien... | ||
Medical condition: Chronic Hepatitis C Infection | ||
Disease: | ||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (GB - no longer in EU/EEA) SE (Completed) ES (Completed) DE (Completed) | ||
Trial results: View results |
EudraCT Number: 2016-000221-39 | Sponsor Protocol Number: M15-539 | Start Date*: 2017-12-14 |
Sponsor Name:AbbVie Inc | ||
Full Title: A Prospective, International, Multicenter, Open-Label, Non-Controlled Study of Safety and Effectiveness of Palivizumab, in Children at High Risk of Severe Respiratory Syncytial Virus (RSV) Infectio... | ||
Medical condition: Severe Respiratory Syncytial Virus (RSV) Infection | ||
Disease: | ||
Population Age: Infants and toddlers, Under 18 | Gender: Male, Female | |
Trial protocol: Outside EU/EEA | ||
Trial results: View results |
EudraCT Number: 2015-000452-24 | Sponsor Protocol Number: M13-576 | Start Date*: 2017-03-27 | |||||||||||
Sponsor Name:AbbVie Deutschland GmbH & Co. KG | |||||||||||||
Full Title: A Follow-up Study to Assess Resistance and Durability of Response to AbbVie Direct-Acting Antiviral Agent (DAA) Therapy (ABT-493 and/or ABT-530) in Subjects Who Participated in Phase 2 or 3 Clinic... | |||||||||||||
Medical condition: Hepatitis C Virus | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-003191-50 | Sponsor Protocol Number: M16-000 | Start Date*: 2017-08-23 | |||||||||||
Sponsor Name:AbbVie Deutschland GmbH & Co. KG | |||||||||||||
Full Title: A Multicenter, Randomized, Double-Blind, Placebo Controlled 52-Week Maintenance and an Open-Label Extension Study of the Efficacy and Safety of Risankizumab in Subjects with Crohn's Disease | |||||||||||||
Medical condition: Crohn's disease | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SK (Ongoing) DK (Ongoing) DE (Ongoing) PT (Ongoing) CZ (Ongoing) GB (GB - no longer in EU/EEA) LV (Ongoing) IE (Ongoing) BG (Ongoing) AT (Ongoing) PL (Ongoing) NL (Ongoing) EE (Ongoing) SE (Ongoing) ES (Ongoing) GR (Ongoing) NO (Ongoing) LT (Ongoing) BE (Ongoing) HR (Ongoing) FR (Ongoing) IT (Ongoing) RO (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2015-002350-13 | Sponsor Protocol Number: M15-410 | Start Date*: 2016-01-18 |
Sponsor Name:AbbVie Deutschland GmbH & Co. KG | ||
Full Title: A Randomized, Open-Label, Multicenter Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Co-Administration of ABT-493 and ABT-530 (or ABT-493/ABT-530) With and Without Ribavirin in Adu... | ||
Medical condition: Hepatitis C Virus (HCV) | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: ES (Completed) GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2012-003073-26 | Sponsor Protocol Number: M13-102 | Start Date*: 2013-10-22 | |||||||||||
Sponsor Name:AbbVie Deutschland GmbH & Co. KG | |||||||||||||
Full Title: A Follow-up Study to Assess Resistance and Durability of Response to AbbVie Direct-Acting Antiviral Agent (DAA) Therapy in Subjects Who Participated in Phase 2 or 3 Clinical Studies for the Treatme... | |||||||||||||
Medical condition: Hepatitis C | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) IE (Completed) DE (Completed) ES (Completed) HU (Prematurely Ended) AT (Completed) BE (Completed) DK (Completed) PT (Completed) PL (Completed) CZ (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-003046-87 | Sponsor Protocol Number: M15-997 | Start Date*: 2017-03-01 | |||||||||||
Sponsor Name:AbbVie Deutschland GmbH & Co. KG | |||||||||||||
Full Title: A multicenter, open Label study to assess the safety and efficacy of rIsankizuMab for MaInTenance in moderate to severe pLaquE type pSoriaSis (LIMMITLESS) | |||||||||||||
Medical condition: Psoriasis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: AT (Completed) SE (Completed) BE (Ongoing) DE (Ongoing) FI (Completed) CZ (Ongoing) PL (Ongoing) PT (Ongoing) ES (Ongoing) FR (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2015-003333-95 | Sponsor Protocol Number: M14-465 | Start Date*: 2015-12-18 | |||||||||||
Sponsor Name:AbbVie Deutschland GmbH & Co. KG | |||||||||||||
Full Title: A Phase 3, Randomized, Double-Blind Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Subjects with Moderately to Severely Active Rheumatoid Arthritis Who are on a Stable Backg... | |||||||||||||
Medical condition: Moderately to Severely Active Rheumatoid Arthritis (RA) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SK (Ongoing) ES (Ongoing) BG (Ongoing) HU (Ongoing) BE (Trial now transitioned) DK (Prematurely Ended) IE (Completed) PT (Trial now transitioned) GB (GB - no longer in EU/EEA) LV (Trial now transitioned) AT (Prematurely Ended) DE (Ongoing) FI (Completed) CZ (Ongoing) HR (Ongoing) LT (Trial now transitioned) GR (Trial now transitioned) RO (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-000641-31 | Sponsor Protocol Number: M14-234 | Start Date*: 2016-09-20 | |||||||||||
Sponsor Name:AbbVie Deutschland GmbH & Co. KG | |||||||||||||
Full Title: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Upadacitinib (ABT-494) for Induction and Maintenance Therapy in Subjects with Moderately to... | |||||||||||||
Medical condition: Ulcerative Colitis | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SK (Completed) NL (Completed) FI (Completed) HU (Completed) CZ (Completed) SE (Completed) PL (Completed) IE (Completed) PT (Completed) DE (Completed) LV (Completed) LT (Completed) AT (Completed) GR (Completed) BE (Completed) EE (Completed) NO (Completed) ES (Completed) GB (GB - no longer in EU/EEA) FR (Completed) HR (Completed) RO (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-001240-35 | Sponsor Protocol Number: M14-433 | Start Date*: 2018-04-17 | |||||||||||
Sponsor Name:AbbVie Deutschland GmbH & Co. KG | |||||||||||||
Full Title: A Multicenter, Randomized, Double-Blind, Placebo Controlled Induction Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Subjects with Moderately to Severely Active Crohn's Disease Who H... | |||||||||||||
Medical condition: Crohn's Disease (CD) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SK (Completed) SE (Completed) DE (Completed) AT (Completed) PT (Completed) BE (Completed) IE (Completed) GB (GB - no longer in EU/EEA) LV (Completed) HU (Completed) NL (Completed) PL (Completed) DK (Completed) LT (Completed) EE (Completed) ES (Completed) BG (Completed) HR (Completed) SI (Completed) FR (Completed) IT (Ongoing) RO (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-000674-38 | Sponsor Protocol Number: M14-533 | Start Date*: 2016-09-20 | |||||||||||
Sponsor Name:AbbVie Deutschland GmbH & Co. KG | |||||||||||||
Full Title: A Phase 3 Multicenter, Long-Term Extension Study to Evaluate the Safety and Efficacy of Upadacitinib (ABT-494) in Subjects with Ulcerative Colitis (UC) | |||||||||||||
Medical condition: Ulcerative Colitis | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SK (Ongoing) NL (Ongoing) CZ (Ongoing) AT (Ongoing) FI (Ongoing) PL (Ongoing) SE (Completed) GB (GB - no longer in EU/EEA) DE (Ongoing) LV (Ongoing) GR (Ongoing) EE (Ongoing) IE (Ongoing) HU (Ongoing) PT (Ongoing) LT (Ongoing) BE (Ongoing) NO (Ongoing) ES (Ongoing) HR (Ongoing) IT (Ongoing) RO (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-003503-64 | Sponsor Protocol Number: M16-298 | Start Date*: 2017-06-12 |
Sponsor Name:Abbvie Deutschland GmbH & Co. KG | ||
Full Title: A Randomized, Double-Blind, Placebo-Controlled Study of Rovalpituzumab Tesirine as Maintenance Therapy Following First-Line Platinum-Based Chemotherapy in Subjects with Extensive Stage Small Cell L... | ||
Medical condition: Extensive Stage Small Cell Lung Cancer (ED SCLC) | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: EE (Prematurely Ended) AT (Completed) DK (Prematurely Ended) FI (Completed) IE (Completed) GB (Completed) SE (Completed) DE (Prematurely Ended) NL (Completed) LV (Prematurely Ended) PT (Prematurely Ended) HU (Completed) GR (Completed) PL (Completed) ES (Prematurely Ended) CZ (Completed) BG (Prematurely Ended) LT (Completed) BE (Completed) HR (Completed) NO (Completed) | ||
Trial results: View results |
EudraCT Number: 2016-000642-62 | Sponsor Protocol Number: M14-675 | Start Date*: 2019-06-13 | |||||||||||
Sponsor Name:AbbVie Deutschland GmbH & Co. KG | |||||||||||||
Full Title: M14-675, A Multicenter, Randomized, Double-Blind, Placebo-Controlled Induction Study to Evaluate the Efficacy and Safety of Upadacitinib (ABT-494) in Subjects with Moderately to Severely Active Ulc... | |||||||||||||
Medical condition: Ulcerative Colitis | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Completed) LV (Completed) PT (Completed) FI (Completed) DE (Completed) GR (Completed) SE (Completed) GB (GB - no longer in EU/EEA) AT (Completed) CZ (Completed) LT (Completed) IE (Completed) HU (Completed) ES (Completed) SK (Completed) PL (Completed) FR (Completed) HR (Completed) NO (Completed) IT (Completed) RO (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-001226-18 | Sponsor Protocol Number: M14-431 | Start Date*: 2018-04-17 | |||||||||||
Sponsor Name:AbbVie Deutschland GmbH & Co. KG | |||||||||||||
Full Title: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Induction Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Subjects with Moderately to Severely Active Crohn's Disease Who H... | |||||||||||||
Medical condition: Crohn's Disease (CD) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SK (Completed) SE (Completed) DK (Completed) AT (Completed) PT (Completed) BE (Completed) IE (Completed) GB (GB - no longer in EU/EEA) LV (Completed) HU (Completed) DE (Completed) PL (Completed) CZ (Completed) LT (Completed) EE (Completed) ES (Completed) BG (Completed) SI (Completed) HR (Ongoing) IT (Ongoing) RO (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-003669-87 | Sponsor Protocol Number: M14-064 | Start Date*: 2018-03-19 |
Sponsor Name:Abbvie Deutschland GmbH & Co. KG | ||
Full Title: Phase 2 Study Comparing Efficacy and Safety of ABT-165 and FOLFIRI vs Bevacizumab and FOLFIRI in Metastatic Colorectal Cancer Previously Treated with Fluoropyrimidine/Oxaliplatin and Bevacizumab | ||
Medical condition: metastatic adenocarcinoma of the colon or rectum previously treated with a regimen containing fluoropyrimidine/oxaliplatin and bevacizumab | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: BE (Prematurely Ended) ES (Prematurely Ended) | ||
Trial results: (No results available) |
EudraCT Number: 2020-000744-55 | Sponsor Protocol Number: M15-954 | Start Date*: 2020-10-21 |
Sponsor Name:AbbVie Deutschland GmbH & Co. KG | ||
Full Title: A Randomized, Double-Blind, Phase 3 Study Evaluating the Safety and Efficacy of Venetoclax in Combination with Azacitidine in Patients Newly Diagnosed with Higher-Risk Myelodysplastic Syndrome (Hig... | ||
Medical condition: Myelodysplastic Syndrome | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (GB - no longer in EU/EEA) HU (Ongoing) DE (Ongoing) CZ (Ongoing) NL (Ongoing) PL (Ongoing) IT (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2015-005398-18 | Sponsor Protocol Number: W15-679 | Start Date*: 2016-07-12 | |||||||||||
Sponsor Name:AbbVie Deutschland GmbH & Co. KG | |||||||||||||
Full Title: Treating patients with early axial spondyloarthritis to target – a 1 year randomized controlled study taking an intense treatment approach versus routine treatment (STRIKE) | |||||||||||||
Medical condition: Axial spondyloarthritis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2019-003753-29 | Sponsor Protocol Number: M19-148 | Start Date*: 2020-05-14 | |||||||||||
Sponsor Name:AbbVie Deutschland GmbH & Co. KG | |||||||||||||
Full Title: A Randomized, Double-Blind, Placebo-Controlled Proof-of-Concept Study to Assess the Safety and Efficacy of Elezanumab in Acute Ischemic Stroke | |||||||||||||
Medical condition: Acute Ischemic Stroke | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2019-003752-36 | Sponsor Protocol Number: M16-077 | Start Date*: 2020-05-14 | |||||||||||
Sponsor Name:AbbVie Deutschland GmbH & Co. KG | |||||||||||||
Full Title: A Randomized, Double-Blind, Placebo-Controlled Proof of Concept Study to Assess the Safety and Efficacy of Elezanumab in Acute Traumatic Cervical Spinal Cord Injury | |||||||||||||
Medical condition: Spinal cord injury (SCI) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-003053-21 | Sponsor Protocol Number: M16-560 | Start Date*: 2019-06-27 | |||||||||||
Sponsor Name:AbbVie Deutschland GmbH & Co. KG | |||||||||||||
Full Title: Randomized, Double-Blind, Double-Dummy, Active Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of ABBV-3373 in Subjects with Moderate to Severe Rheumatoid Arth... | |||||||||||||
Medical condition: Moderate to Severe Rheumatoid Arthritis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: PL (Completed) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
